 Jason Christie
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purkinje Cells | 9 | 2023 | 68 | 3.880 |
Why?
| | Cerebellum | 11 | 2024 | 219 | 3.480 |
Why?
| | Interneurons | 11 | 2023 | 124 | 2.570 |
Why?
| | Dendrites | 6 | 2021 | 105 | 2.300 |
Why?
| | Cerebellar Cortex | 4 | 2019 | 21 | 1.950 |
Why?
| | Axons | 7 | 2019 | 198 | 1.840 |
Why?
| | Calcium Signaling | 7 | 2021 | 248 | 1.810 |
Why?
| | Action Potentials | 9 | 2021 | 509 | 1.750 |
Why?
| | Presynaptic Terminals | 4 | 2017 | 94 | 1.590 |
Why?
| | Synapses | 5 | 2019 | 433 | 1.490 |
Why?
| | Movement | 4 | 2022 | 291 | 1.250 |
Why?
| | Potassium Channels | 4 | 2017 | 144 | 1.170 |
Why?
| | Neural Inhibition | 3 | 2018 | 176 | 1.150 |
Why?
| | Learning | 3 | 2022 | 434 | 1.100 |
Why?
| | Patch-Clamp Techniques | 10 | 2018 | 291 | 0.800 |
Why?
| | Neuronal Plasticity | 3 | 2021 | 305 | 0.800 |
Why?
| | Olfactory Bulb | 4 | 2006 | 99 | 0.750 |
Why?
| | Synaptic Transmission | 7 | 2022 | 295 | 0.740 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 5 | 2014 | 227 | 0.680 |
Why?
| | Shaw Potassium Channels | 2 | 2017 | 4 | 0.630 |
Why?
| | Olivary Nucleus | 1 | 2019 | 15 | 0.600 |
Why?
| | Motor Activity | 2 | 2021 | 717 | 0.570 |
Why?
| | Mice | 18 | 2024 | 18172 | 0.530 |
Why?
| | Nerve Net | 2 | 2018 | 276 | 0.530 |
Why?
| | Animals | 27 | 2024 | 37697 | 0.530 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 69 | 0.510 |
Why?
| | Microscopy, Fluorescence | 2 | 2015 | 416 | 0.510 |
Why?
| | Functional Neuroimaging | 1 | 2015 | 60 | 0.470 |
Why?
| | Connexins | 2 | 2006 | 53 | 0.450 |
Why?
| | Lung Transplantation | 3 | 2024 | 323 | 0.430 |
Why?
| | Receptors, Presynaptic | 1 | 2014 | 10 | 0.430 |
Why?
| | Psychomotor Performance | 1 | 2017 | 328 | 0.420 |
Why?
| | Calcium | 4 | 2017 | 1179 | 0.400 |
Why?
| | Mice, Transgenic | 4 | 2021 | 2180 | 0.390 |
Why?
| | Excitatory Amino Acid Antagonists | 5 | 2009 | 106 | 0.380 |
Why?
| | Brain Mapping | 1 | 2015 | 534 | 0.380 |
Why?
| | Ion Channel Gating | 2 | 2009 | 91 | 0.370 |
Why?
| | Behavior, Animal | 1 | 2015 | 515 | 0.370 |
Why?
| | Reflex, Vestibulo-Ocular | 2 | 2022 | 26 | 0.360 |
Why?
| | Periodicity | 2 | 2022 | 56 | 0.320 |
Why?
| | Ion Channels | 1 | 2009 | 130 | 0.290 |
Why?
| | Pyramidal Cells | 1 | 2009 | 79 | 0.290 |
Why?
| | Optogenetics | 2 | 2021 | 110 | 0.280 |
Why?
| | Calcium Channels | 1 | 2008 | 156 | 0.270 |
Why?
| | Touch | 2 | 2018 | 36 | 0.260 |
Why?
| | Touch Perception | 2 | 2018 | 19 | 0.260 |
Why?
| | Haploinsufficiency | 2 | 2024 | 55 | 0.250 |
Why?
| | In Vitro Techniques | 5 | 2009 | 1062 | 0.250 |
Why?
| | Receptors, AMPA | 4 | 2014 | 143 | 0.240 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 2006 | 39 | 0.240 |
Why?
| | Olfactory Pathways | 1 | 2006 | 38 | 0.240 |
Why?
| | Rats, Sprague-Dawley | 6 | 2010 | 2523 | 0.240 |
Why?
| | Neurons, Afferent | 1 | 2006 | 101 | 0.230 |
Why?
| | Rats | 7 | 2010 | 5585 | 0.230 |
Why?
| | Membrane Potentials | 4 | 2009 | 280 | 0.230 |
Why?
| | Signal Transduction | 2 | 2017 | 5163 | 0.220 |
Why?
| | DiGeorge Syndrome | 1 | 2024 | 34 | 0.220 |
Why?
| | T-Box Domain Proteins | 1 | 2024 | 102 | 0.210 |
Why?
| | Cerebellar Vermis | 1 | 2023 | 5 | 0.210 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2018 | 124 | 0.210 |
Why?
| | Microscopy, Confocal | 2 | 2019 | 324 | 0.200 |
Why?
| | Glutamic Acid | 4 | 2008 | 256 | 0.200 |
Why?
| | Mice, Inbred C57BL | 4 | 2018 | 5967 | 0.200 |
Why?
| | Receptors, GABA-A | 3 | 2022 | 141 | 0.180 |
Why?
| | Neurons | 3 | 2018 | 1626 | 0.180 |
Why?
| | Gold Colloid | 1 | 2021 | 1 | 0.170 |
Why?
| | Channelrhodopsins | 1 | 2021 | 19 | 0.170 |
Why?
| | Graft Survival | 1 | 2024 | 518 | 0.170 |
Why?
| | Transplants | 1 | 2021 | 39 | 0.170 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2021 | 45 | 0.170 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2022 | 91 | 0.170 |
Why?
| | Electric Stimulation | 3 | 2009 | 281 | 0.170 |
Why?
| | Tissue Donors | 1 | 2024 | 412 | 0.160 |
Why?
| | Microscopy, Electron | 1 | 2021 | 415 | 0.160 |
Why?
| | Graft Rejection | 1 | 2024 | 550 | 0.160 |
Why?
| | Endocannabinoids | 1 | 2021 | 68 | 0.160 |
Why?
| | Metal Nanoparticles | 1 | 2021 | 85 | 0.160 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 65 | 0.160 |
Why?
| | Hippocampus | 1 | 2006 | 944 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2024 | 330 | 0.160 |
Why?
| | Wakefulness | 1 | 2021 | 170 | 0.150 |
Why?
| | Piperidines | 1 | 2021 | 220 | 0.150 |
Why?
| | Excitatory Amino Acid Agonists | 2 | 2009 | 41 | 0.150 |
Why?
| | ras GTPase-Activating Proteins | 1 | 2018 | 15 | 0.150 |
Why?
| | Physical Stimulation | 1 | 2019 | 68 | 0.150 |
Why?
| | Water | 1 | 2022 | 469 | 0.140 |
Why?
| | Male | 11 | 2024 | 70910 | 0.140 |
Why?
| | Sensation Disorders | 1 | 2018 | 41 | 0.140 |
Why?
| | Evoked Potentials, Motor | 1 | 2018 | 50 | 0.140 |
Why?
| | Somatosensory Cortex | 1 | 2018 | 41 | 0.140 |
Why?
| | Reperfusion Injury | 1 | 2021 | 292 | 0.140 |
Why?
| | Photic Stimulation | 1 | 2019 | 257 | 0.140 |
Why?
| | Lung Injury | 1 | 2021 | 224 | 0.140 |
Why?
| | Acoustic Stimulation | 1 | 2019 | 325 | 0.130 |
Why?
| | Pyrazoles | 1 | 2021 | 490 | 0.130 |
Why?
| | Neural Pathways | 1 | 2019 | 305 | 0.130 |
Why?
| | Tongue | 1 | 2017 | 81 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 771 | 0.120 |
Why?
| | Female | 9 | 2024 | 76624 | 0.120 |
Why?
| | Quinoxalines | 2 | 2009 | 67 | 0.120 |
Why?
| | Lipoproteins, HDL | 1 | 2016 | 78 | 0.120 |
Why?
| | Primary Graft Dysfunction | 1 | 2016 | 34 | 0.120 |
Why?
| | Drinking Behavior | 1 | 2015 | 13 | 0.120 |
Why?
| | Vibrissae | 1 | 2015 | 10 | 0.120 |
Why?
| | Protein Kinase C | 1 | 2017 | 252 | 0.120 |
Why?
| | Shaker Superfamily of Potassium Channels | 1 | 2014 | 4 | 0.110 |
Why?
| | Cholesterol | 1 | 2016 | 404 | 0.110 |
Why?
| | Electrophysiological Phenomena | 1 | 2014 | 58 | 0.100 |
Why?
| | Autoantibodies | 1 | 2021 | 1482 | 0.100 |
Why?
| | Fluorescent Dyes | 1 | 2014 | 322 | 0.090 |
Why?
| | 2-Amino-5-phosphonovalerate | 2 | 2003 | 10 | 0.090 |
Why?
| | Brain | 2 | 2021 | 2875 | 0.090 |
Why?
| | Egtazic Acid | 1 | 2010 | 38 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1727 | 0.080 |
Why?
| | Iontophoresis | 1 | 2009 | 13 | 0.080 |
Why?
| | Coronary Artery Disease | 1 | 2016 | 721 | 0.080 |
Why?
| | N-Methylaspartate | 1 | 2009 | 43 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2016 | 723 | 0.080 |
Why?
| | Glutamates | 1 | 2009 | 62 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2021 | 2862 | 0.070 |
Why?
| | Organ Culture Techniques | 1 | 2008 | 157 | 0.070 |
Why?
| | Long-Term Synaptic Depression | 1 | 2008 | 55 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2009 | 196 | 0.070 |
Why?
| | Animals, Newborn | 1 | 2009 | 875 | 0.060 |
Why?
| | Piperazines | 1 | 2009 | 376 | 0.060 |
Why?
| | Cerebral Cortex | 1 | 2009 | 463 | 0.060 |
Why?
| | Indoles | 1 | 2009 | 475 | 0.060 |
Why?
| | Synaptic Vesicles | 1 | 2006 | 41 | 0.060 |
Why?
| | Temporal Bone | 1 | 2024 | 43 | 0.050 |
Why?
| | Gap Junctions | 1 | 2005 | 64 | 0.050 |
Why?
| | Osteoblasts | 1 | 2024 | 136 | 0.050 |
Why?
| | Long-Term Potentiation | 1 | 2006 | 200 | 0.050 |
Why?
| | Skull | 1 | 2024 | 151 | 0.050 |
Why?
| | Tetrodotoxin | 1 | 2003 | 41 | 0.050 |
Why?
| | 4-Aminopyridine | 1 | 2003 | 30 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2003 | 46 | 0.050 |
Why?
| | Pyridazines | 1 | 2003 | 56 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4483 | 0.050 |
Why?
| | Chondrocytes | 1 | 2024 | 230 | 0.050 |
Why?
| | Memory Disorders | 1 | 2023 | 184 | 0.050 |
Why?
| | Mice, Inbred mdx | 1 | 2022 | 12 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2021 | 24 | 0.040 |
Why?
| | Receptor, Endothelin A | 1 | 2021 | 63 | 0.040 |
Why?
| | Bronchiolitis Obliterans | 1 | 2021 | 64 | 0.040 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2001 | 19 | 0.040 |
Why?
| | GABA Antagonists | 1 | 2001 | 35 | 0.040 |
Why?
| | Glycosylation | 1 | 2021 | 169 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 413 | 0.040 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 66 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 357 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 287 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4167 | 0.030 |
Why?
| | Humans | 8 | 2024 | 142526 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2005 | 3081 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2024 | 2008 | 0.030 |
Why?
| | Binding Sites | 1 | 2000 | 1317 | 0.030 |
Why?
| | Allografts | 1 | 2016 | 150 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4112 | 0.030 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 157 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2021 | 651 | 0.030 |
Why?
| | Lung Diseases | 1 | 2021 | 786 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 5270 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 318 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3562 | 0.030 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1045 | 0.020 |
Why?
| | Global Health | 1 | 2016 | 387 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1995 | 0.020 |
Why?
| | Cognition | 1 | 2018 | 1249 | 0.020 |
Why?
| | Middle Aged | 2 | 2024 | 35049 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2227 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10593 | 0.020 |
Why?
| | Adult | 2 | 2024 | 39715 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2831 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 4207 | 0.010 |
Why?
| | Aged | 1 | 2020 | 25117 | 0.010 |
Why?
|
|
Christie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|